Initially discovered in 1938 as a “fertility factor,” vitamin E now refers to eight different isoforms that belong to two categories, four saturated analogues (α, β, γ, and δ) called tocopherols and four unsaturated analogues referred to as tocotrienols. While the tocopherols have been investigated extensively, little is known about the tocotrienols. Very limited studies suggest that both the molecular and therapeutic targets of the tocotrienols are distinct from those of the tocopherols. For instance, suppression of inflammatory transcription factor NF-κB, which is closely linked to tumorigenesis and inhibition of HMG-CoA reductase, mammalian DNA polymerases and certain protein tyrosine kinases, is unique to the tocotrienols. This review examines in detail the molecular targets of the tocotrienols and their roles in cancer, bone resorption, diabetes, and cardiovascular and neurological diseases at both preclinical and clinical levels. As disappointment with the therapeutic value of the tocopherols grows, the potential of these novel vitamin E analogues awaits further investigation.
Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases
Please Share This Share this content
- Opens in a new window Twitter
- Opens in a new window Facebook
- Opens in a new window Google+
- Opens in a new window Pinterest
- Opens in a new window LinkedIn
- Opens in a new window Viber
- Opens in a new window VK
- Opens in a new window Reddit
- Opens in a new window Tumblr
- Opens in a new window Viadeo
- Opens in a new window WhatsApp